




HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT 2020



PHRAMONGKUTKLAO HOSPITAL

ARMY MEDICAL DEPARTMENT

MINISTRY OF DEFENCE

THAILAND

ISBN : 978-616-422-078-2

PHRAMONGKUTKLAO HOSPITAL EXCELLENT CENTER OF CANCER CARE

2020

Title	Phramongkutklao Hospital Cancer Registry Report 2020
Editorial Board	Naiyarat Prasongsook, M.D. Chairman of cancer Registry Committee, Chairman Excellent Center of Cancer Care. Kritsada Srithanaphakarangkul, M.D. Chairman Cancer of the Data Information committee
Published by	Clinical Epidemiology Unit and Oncology Department, Phramongkutklao Hospital 315 Chalermprakiet Building, Ratchawithi Road, Ratchathewi District, Thung Phaya Thai Subdistrict. Bangkok 10400 Tel. & Fax. : 027633047, 023547780
Published Edition Physical	2021 Thirteenth 71 pages
ISBN	978-616-422-078-2



EXCELLENT CENTER OF CANCER CARE

HOSPITAL-BASED CANCER REGISTRY

ANNUAL REPORT

2020

Phramongkutklao Hospital
Royal Thai Army Medical Department
Ministry of Defence
Bangkok, Thailand

Edited By
Y.Tanapat and K.Srithanaphakarangkul
Edition : December, 2020
ISBN : 978-616-422-078-2

MESSAGE FROM DIRECTOR OF PHRAMONGKUTKLAO HOSPITAL




The Phramongkutklao Hospital is proud to present the Cancer Registry Report 2020. The report collects information on all new cancer cases. Data collected include the clinical characteristics of the cancer (site, histology, behavior, grade, extent of disease) and treatment details on the cancer patient. The registry has a comprehensive quality assurance program in place to ensure that the data are complete, accurate and timely.

I would like to thank all our collaborators for their eflust in providing data presented in this volume. I would like to express my gratitude to the devoted staffs of cancer registry in all cancer units for

the immense amount of work that has been done in preparation of the statistics and graphics for this volume.

A handwritten signature in blue ink, consisting of stylized, flowing letters.

Surasak Tanudsintum, Maj.Gen.
Director General of Phramongkutklao Hospital
Dean of Phramongkutklao College of Medicine
Major General, Royal Thai Army



INTRODUCTION

The Phramongkutklao Hospital Cancer Registry Report 2020 is a hospital based cancer registry of new cancer patients initially diagnosed or initially treated at Phramongkutklao Cancer Center from January 1, 2020 to December 31, 2020. All new cancer patients registered during the mentioned period were treated at the various Cancer Units under The Excellent center of Cancer Care, Phramongkutklao Hospital. Patients were either primarily diagnosed or referred from army hospitals (under supervision of the Royal Thai Army Medical Department) as well as public and private hospitals. The objective of this is to report new cancer patients regarding method of diagnosis, pathological types, staging, behavior, grading, extension and primary treatment modalities. Phramongkutklao Hospital has initiated a hospital cancer registry system based on the existing hospital data management system since 2009. This system has enabled physicians and nurses taking care of cancer patients to update patient information on the cancer registry at Cancer Units on a real-time basis. Thus information obtained can be corrected and updated by persons in charge of patient care at the time of the patient's hospital visit. This process should contribute to the validity of information in the Cancer Registry.

This Cancer Registry Report would not be possible without the dedicated input of data from the staff of the Cancer Clinics and the Cancer Units from different departments at Phramongkutklao Cancer Center.




Assist.Prof. Naiyarat Prasongsook, M.D., M.S., Lt.Col.

Chairman

Cancer Registry Committee


Phramongkutklao Cancer Center



EXCELLENT CENTER OF CANCER CARE

PHRAMONGKUTKLAO HOSPITAL

1.	Maj.Gen.Surasak	Tanudsintum	Consultant
2.	Col. Pariyanan	Jaruchinda	Consultant
3.	Col. Rachata	Lumkul	Consultant
4.	Col. Kasan	Seetalarom	Consultant
5.	Col. Naiyarat	Prasongsook	Chairman of Administor Committee
6.	Col. Sukchai	Satthaporn.	Member
7.	Col. Chinakrit	BoonyaUssadorn	Member
8.	Col. Satit	Siriboonrid	Member
9.	Col. Sirinthip	Songwutwichai	Member
10.	Col. Chanchai	Traivaree	Member
11.	Col. Phutsapong	Srisawat	Member
12.	Lt.Col. Sithapan	Munjupong	Member
13.	Col. Kristsanamon	Rittiluechai	Member
14.	Lt.Col. Chonlada	Laoruagroj	Member
15.	Col Vana	Sangsasri	Member
16.	Lt.Col. Jarey	Ketsirichai	Member
17.	Lt.Col. Siriwimon	Saichaemchan	Member
18.	Lt.Col. Watcharaporn	bourchom	Member
19.	Lt.Col. Kanya	Ketkong	Member
20.	Lt.Col. Nattapoang	Binsri	Member
21.	Lt.Col. Chalinee	Monseereenusorn	Member
22.	Lt.Col. Usa	Rittitada	Member
23.	Lt.Col. Supicha	Wongphun	Member
24.	Lt.Col. Kannadit	Prayongratana	Member
25.	Maj. Suvicha	Khampunnip	Member
26.	Maj. Sujitra	Shoolerd	Member
27.	Maj. Weerawan	Kaesai	Member
28.	Maj. Piyanuch	Srisuk	Member
29.	Maj. Nongnut	Seedapalee	Member
30.	Lt.Col. Rapeeporn	Kanchanapachana	Member



EXCELLENT CENTER OF CANCER CARE PHRAMONGKUTKLAO HOSPITAL

31.	Maj. Chetsuda	Khwanakorn	Member
32.	Capt. Sutipat	Pairojboriboon	Member
33.	Lt. Chatchanin	Ajalanond	Member
34.	Dr. Panjawit	Wuttiapanich	Member
35.	Maj. wanvipa	Malaithong	Member
36.	Capt. Supittha	Tongpit	Member
37.	Maj. Phapasi	Punphasoed	Member
38.	Col. Jariya	Ketkaeo	Member
39.	Col. Waniknan	Hatsadin	Member
40.	Capt. Patcharaporn	liamsuwan	Member
41.	Capt. Atcharaporn	Sittichai	Member

CANCER REGISTRY STAFF

1. Miss Rungthip Boonyai, B.Com. (Computer)
2. Miss Chawanphat Udomphon, B.Sc. (Statistics)




TABLE OF CONTENTS

Title		
List of tables :		Page
Table 1	Distribution of new cancer patients by gender : 2020	1
Table 2	Number of all new patients : 2009-2020	2
Table 3	Ten leading primary sites of new cancer patients by gender : 2020	3
Table 4	Ten leading primary sites of new cancer patients in male : 2020	4
Table 5	Ten leading primary sites of new cancer patients in female : 2020	5
Table 6	Distribution of new cancer patients by age group and gender : 2020	6
Table 7	Distribution of new cancer patients by stage and gender : 2020	7
Table 8	Histologic differentiation of all solid cancer : 2020	8
Table 9	Immunophenotype designation for lymphomas and leukaemias : 2020	9
Table 10	Distribution of new cancer patients by extension and gender : 2020	9
Table 11	Distribution of new cancer patients by method and gender : 2020	10
Table 12	Distribution of new cancer patients by treatment modalities and gender : 2020	11
Table 13	Distribution of new cancer patients by treatment unit and gender: 2020	12
Table 14	Distribution of new cancer patients by status 2020	13
Table 15	Distribution of new cancer patients by follow up status and gender 2020	13
Table 16	Distribution of new military personnel cancer patients by age group and gender : 2020	14
Table 17	Distribution of new cancer patients by rank and gender : 2020	15
Table 18	Distribution of new childhood cancer patients (age 0-19) by age group and gender : 2020	16
Table 19	Distribution of new childhood cancer patients (age 0-19) by primary sites : 2020	16
Table 20	Distribution of new childhood cancer patients (age 0-19) by treatment modalities and gender : 2020	17
Table 21	Distribution of new childhood cancer patients (age 0-19) by method and gender : 2020	17
Table 22	Distribution of new childhood cancer patients (age 0-19) by type of extension and gender : 2020	18
Table 23	Distribution of new childhood cancer patients (age 0-19) by follow up and gender : 2020	18
Table 24	Number of new cancer patient stage and gender : 2020	19-23




TABLE OF CONTENTS

Title		
List of tables :		Page
Description of the leading site of cancers ordinal 1-3		
1. Breast cancer		
Table 25	Trend of breast cancer in Phramongkutklao hospital : 2009-2020	25
Table 26	Distribution of new breast cancer patients by age group and gender : 2020	26
Table 27	Distribution of new breast cancer patients by stage and gender : 2020	27
Table 28	Distribution of new breast cancer patients by method and gender : 2020	28
Table 29	Distribution of new breast cancer patients by extension and gender: 2020	28
Table 30	Distribution of new breast cancer patients by treatment modalities and gender : 2020	29
Table 31	Distribution of new breast cancer patients by follow up status and gender : 2020	29
2. Colon and rectum cancer		
Table 32	Trend of colon and rectum cancer in Phramongkutklao hospital : 2009-2020	30
Table 33	Distribution of new colon and rectum cancer patients by age group and gender : 2020	31
Table 34	Distribution of new colon and rectum cancer patients by stage and gender : 2020	32
Table 35	Distribution of new colon and rectum cancer patients by method and gender : 2020	33
Table 36	Distribution of new colon and rectum cancer patients by extension and gender : 2020	33
Table 37	Distribution of new colon and rectum cancer patients by treatment modalities and gender : 2020	34
Table 38	Distribution of new colon and rectum cancer patients by follow up status and gender : 2020	34
3. Trachea, bronchus and lung cancer		
Table 39	Trend of trachea, bronchus and lung cancer in Phramongkutklao hospital : 2009-2020	35
Table 40	Distribution of new trachea, bronchus and lung cancer patients by age group and gender : 2020	36
Table 41	Distribution of new trachea, bronchus and lung cancer patients by stage and gender : 2020	37
Table 42	Distribution of new trachea, bronchus and lung cancer patients by method and gender : 2020	38
Table 43	Distribution of new trachea, bronchus and lung cancer patients by extension and gender: 2020	38
Table 44	Distribution of new trachea, bronchus and lung cancer patients by treatment modalities and gender : 2020	39
Table 45	Distribution of new trachea, bronchus and lung cancer patients by follow up status and gender : 2020	39




TABLE OF CONTENTS

Title		
List of tables :		Page
Description of the leading site of cancers ordinal 4-6		
4. Thyroid cancer		
Table 46	Distribution of new Thyroid cancer patients by age group and gender : 2020	40
Table 47	Distribution of new Thyroid cancer patients by stage and gender : 2020	41
Table 48	Distribution of new Thyroid cancer patients by method and gender : 2020	42
Table 49	Distribution of new Thyroid cancer patients by extension and gender : 2020	42
Table 50	Distribution of new Thyroid cancer patients by treatment modalities and gender : 2020	43
Table 51	Distribution of new Thyroid cancer patients by follow up status and gender : 2020	43
5. Liver and intrahepatic bile ducts cancer		
Table 52	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2020	44
Table 53	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender : 2020	45
Table 54	Distribution of new Liver and intrahepatic bile ducts cancer patients by method and gender: 2020	46
Table 55	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2020	46
Table 56	Distribution of new Liver and intrahepatic bile ducts cancer patients by treatment modalities and gender: 2020	47
Table 57	Distribution of new Liver and intrahepatic bile ducts cancer patients by follow up status and gender: 2020	47
6. Non - Hodgkin's Lymphoma cancer		
Table 58	Distribution of new Non - Hodgkin's Lymphoma cancer patients by age group and gender: 2020	48
Table 59	Distribution of new Non - Hodgkin's Lymphoma cancer patients by stage and gender: 2020	49
Table 60	Distribution of new Non - Hodgkin's Lymphoma cancer patients by method and gender: 2020	50
Table 61	Distribution of new Non - Hodgkin's Lymphoma cancer patients by extension and gender: 2020	50
Table 62	Distribution of new Non - Hodgkin's Lymphoma cancer patients by treatment modalities and gender: 2020	51
Table 63	Distribution of new Non - Hodgkin's Lymphoma cancer patients follow up status and gender: 2020	51




TABLE OF CONTENTS

Title		
List of tables :		Page
Number of cases by age-group in sex		
Table 64	Distribution of new cancer in male by age - group : 2020	52
Table 65	Distribution of new cancer in female by age - group : 2020	53
Distribution of new cancer in by morphology and site : 2020		
Table 66	Distribution of new cancer patients by morphology and site : 2020	54-66
Distribution of new cancer patients: 2016-2020		
Table 67	Distribution of new cancer patients by follow up and gender: 2016-2020	67
Table 68	The leading primary sites of new cancer by gender: 2016-2020	67
Table 69	The leading primary sites of new cancer by follow up and gender: 2016-2020	68
Table 70	The 60 months survival time (median) top 6 by gender in 2016 - 2020	68




FIGURE OF CONTENTS

Title		
List of tables :		Page
Figure 1	All new cancer cases in Phramongkutklao hospital :2009-2020	1
Figure 2	Trend of number of all new cancer patients by gender :2009-2020	2
Figure 3	Ten leading primary sites of new cancer patients by gender: 2020	3
Figure 4	Ten leading primary sites of new cancer patients in male : 2020	4
Figure 5	Ten leading primary sites of new cancer patients in female : 2020	5
Figure 6	Distribution of new cancer patients by age group and gender : 2020	6
Figure 7	Distribution of new cancer patients by stage and gender : 2020	7
Figure 8	Histologic differentiation of all solid cancer : 2020	8
Figure 9	Distribution of new cancer patients by extension and gender : 2020	9
Figure 10	Distribution of new cancer patients by method and gender : 2020	10
Figure 11	Distribution of new cancer patients by treatment unit and gender: 2020	12
Figure 12	Distribution of new cancer patients by follow up status : 2020	13
Figure 13	Distribution of new military personnel cancer patients by age group and gender : 2020	14
Figure 14	Distribution of new cancer patients by rank and gender : 2020	15




FIGURE OF CONTENTS

Title		
List of tables :		Page
Description of the leading site of cancers ordinal 1-6		
1. Breast cancer		
Figure 15	Distribution of new Breast cancer patients by age group and gender : 2020	26
Figure 16	Distribution of new Breast cancer patients by stage and gender : 2020	27
Figure 17	Distribution of new Breast cancer patients by extension and gender : 2020	28
2. Colon and rectum cancer		
Figure 18	Distribution of new Colon and rectum cancer patients by age group and gender : 2020	31
Figure 19	Distribution of new Colon and rectum cancer patients by stage and gender : 2020	32
Figure 20	Distribution of new Colon and rectum cancer patients by extension and gender : 2020	33
3. Trachea, bronchus and lung cancer		
Figure 21	Distribution of new Trachea, bronchus and lung cancer patients by age group and gender :2020	36
Figure 22	Distribution of new Trachea, bronchus and lung cancer patients by stage and gender : 2020	37
Figure 23	Distribution of new Trachea, bronchus and lung cancer patients by extension and gender : 2020	38
4. Thyroid cancer		
Figure 24	Distribution of new Thyroid cancer patients by age group and gender : 2020	40
Figure 25	Distribution of new Thyroid cancer patients by stage and gender : 2020	41
Figure 26	Distribution of new Thyroid cancer patients by extension and gender : 2020	42
5. Liver and intrahepatic bile ducts cancer		
Figure 27	Distribution of new Liver and intrahepatic bile ducts cancer patients by age group and gender: 2020	44
Figure 28	Distribution of new Liver and intrahepatic bile ducts cancer patients by stage and gender: 2020	45
Figure 29	Distribution of new Liver and intrahepatic bile ducts cancer patients by extension and gender: 2020	46
6. Non - Hodgkin's Lymphoma cancer		
Figure 30	Distribution of new Non - Hodgkin's Lymphoma cancer patients by age group and gender : 2020	48
Figure 31	Distribution of new Non - Hodgkin's Lymphoma cancer patients by stage and gender : 2020	49
Figure 32	Distribution of new Non - Hodgkin's Lymphoma cancer patients by extension and gender : 2020	50





FIGURE OF CONTENTS

Title		
List of tables :		Page
Distribution of the 60 month survival rate of cancers in 2016-2020		
Figure 32	The 60 months survival rate (top 6) in 2016 – 2020	69
Figure 33	The 60 months survival rate (top 6) by male in 2016 – 2020	70
Figure 34	The 60 months survival rate (top 6) by Female in 2016 – 2020	71



2020 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT




TABLE 1 DISTRIBUTION OF NEW CANCER PATIENTS BY GENDER : 2020

Type of patients	Number of cases
Total new hospital patients	42,412 (100.00%)
Total new cancer patients	1,608 (3.79%)
Gender distribution of cancer	
• Male	800 (49.75%)
• Female	808 (50.25%)

FIGURE 1 : ALL NEW CANCER CASE IN PHRAMONGKUTKLOA HOSPITAL: 2009 – 2020




TABLE 2

NUMBER OF ALL NEW PATIENTS : 2009 – 2020

Years	New patient	New cancer case	Case	Male		Female	
	Number	Number	Percent	Number	Percent	Number	Percent
2552 (2009)	50,451	1,623	3.22	851	1.69	772	1.53
2553 (2010)	48,054	1,640	3.41	847	1.76	793	1.65
2554 (2011)	50,148	1,730	3.45	927	1.85	803	1.60
2555 (2012)	58,244	1,898	3.26	985	1.69	913	1.57
2556 (2013)	66,151	1,801	2.72	897	1.36	904	1.37
2557 (2014)	68,306	1,856	2.72	947	1.39	909	1.33
2558 (2015)	55,484	1,536	2.77	801	1.44	735	1.32
2559 (2016)	59,191	1,771	2.99	881	1.49	890	1.50
2560 (2017)	58,320	1,539	2.64	779	1.34	760	1.30
2561 (2018)	55,771	1,666	2.99	886	1.59	780	1.40
2562 (2019)	57,049	1,720	3.01	885	1.55	835	1.46
2563 (2020)	42,412	1,608	3.79	800	1.89	808	1.91

FIGURE 2 : TREND OF NUMBER OF ALL NEW PATIENTS BY GENDER: 2009 – 2020






TABLE 3 TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER : 2020

Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Breast	3	0.6	181	29.9	184	16.6
2	Colon&Rectosigmoid junction & Rectum	107	21.4	72	11.9	179	16.2
3	Trachea, bronchus & lung	109	21.8	63	10.4	172	15.6
4	Thyroid gland	26	5.2	91	15.0	117	10.6
5	Liver & intrahepatic bile ducts	83	16.6	32	5.3	115	10.4
6	Non-Hodgkin's lymphoma	54	10.8	48	7.9	102	9.2
7	Prostate gland	84	16.8	0	0.0	84	7.6
8	leukaemia	34	6.8	26	4.3	60	5.4
9	Cervix	0	0.0	51	8.4	51	4.6
10	Corpus uteri	0	0.0	42	6.9	42	3.8
Total		500	100	606	100	1106	100

FIGURE 3: TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS BY GENDER: 2020





TABLE 4

TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE : 2020

Ordinal	Primary site	Number	Percent
1	Trachea, bronchus & lung	109	13.63
2	Colon & Rectosigmoid junction & Rectum	107	13.38
3	Prostate gland	84	10.50
4	Liver & intrahepatic bile ducts	83	10.38
5	Non-Hodgkin's lymphoma	54	6.75
6	leukaemia	34	4.25
7	Kidney, renal pelvis & ureter	29	3.63
8	Bladder	28	3.50
9	Thyroid gland	26	3.25
10	Lip & Oral cavity	24	3.00

FIGURE 4 : TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN MALE: 2020





Ordinal	Primary site	Number	Percent
1	Breast	181	22.40
2	Thyroid gland	91	11.26
3	Colon & Rectosigmoid junction & Rectum	72	8.91
4	Trachea, bronchus & lung	63	7.80
5	Cervix	51	6.31
6	Non-Hodgkin's lymphoma	48	5.94
7	Corpus uteri	42	5.20
8	Liver & intrahepatic bile ducts	32	3.96
9	Ovary	27	3.34
10	leukaemia	26	3.22

FIGURE 5 : TEN LEADING PRIMARY SITES OF NEW CANCER PATIENTS IN FEMALE: 2020




TABLE 6 DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	4	0.5	5	0.6	9	0.6
5 – 9	7	0.9	1	0.1	8	0.5
10 – 14	2	0.3	3	0.4	5	0.3
15 – 19	3	0.4	1	0.1	4	0.2
20 – 24	8	1.0	10	1.2	18	1.1
25 – 29	14	1.8	22	2.7	36	2.2
30 – 34	16	2.0	34	4.2	50	3.1
35 – 39	23	2.9	55	6.8	78	4.9
40 – 44	34	4.3	57	7.1	91	5.7
45 – 49	57	7.1	66	8.2	123	7.6
50 – 54	62	7.8	91	11.3	153	9.5
55 – 59	107	13.4	115	14.2	222	13.8
60 – 64	117	14.6	88	10.9	205	12.7
65 – 69	117	14.6	73	9.0	190	11.8
70 – 74	89	11.1	65	8.0	154	9.6
75 – 79	75	9.4	46	5.7	121	7.5
80 – 84	40	5.0	42	5.2	82	5.1
85 +	25	3.1	34	4.2	59	3.7
Total	800	100.0	808	100.0	1608	100.0

Majority of cases


FIGURE 6 : DISTRIBUTION OF NEW CANCER PATIENTS BY AGE GROUP AND GENDER: 2020



TABLE 7 DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER : 2020

Staging	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	118	14.8	200	24.8	318	19.8
Stage II	195	24.4	220	27.2	415	25.8
Stage III	188	23.5	188	23.3	376	23.4
Stage IV	249	31.1	165	20.4	414	25.7
No stage	48	6.0	31	3.8	79	4.9
Unknown	2	0.3	4	0.5	6	0.4
Total	800	100.0	808	100.0	1608	100.0

No stage: manual system including leukaemia and brain

FIGURE 7 : DISTRIBUTION OF NEW CANCER PATIENTS BY STAGE AND GENDER: 2020




TABLE 8

HISTOLOGIC DIFFERENTIATION OF ALL SOLID CANCER : 2020

Grade	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Well differentiated	76	11.0	72	10.0	148	10.5
Moderately differentiated	161	23.2	224	31.1	385	27.2
Poorly differentiated	173	25.0	197	27.3	370	26.2
Undifferentiated	39	5.6	6	0.8	45	3.2
Differentiated not Determined	244	35.2	222	30.8	466	33.0
Total	693	100.0	721	100.0	1414	100.0

FIGURE 8 : HISTOLOGIC DIFFERENTIATION OF ALL SOLID CANCER: 2020






TABLE 9 IMMUNOPHENOTYPE DESIGNATION FOR LYMPHOMAS AND LEUKAEMIAS : 2020

Immunophenotype designation	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
T – Cell	31	29.0	36	41.4	67	34.5
B – Cell	76	71.0	51	58.6	127	65.5
Total	107	100.0	87	100.0	194	100.0

TABLE 10 DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extend	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	496	62.0	550	68.1	1046	65.0
Direct extension	2	0.3	2	0.2	4	0.2
Regional lymph nodes	106	13.3	121	15.0	227	14.1
Distant metastasis	196	24.5	135	16.7	331	20.6
Total	800	100.0	808	100.0	1608	100.0

FIGURE 9 : DISTRIBUTION OF NEW CANCER PATIENTS BY EXTENSION AND GENDER: 2020




TABLE 11 DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER : 2020

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	44	5.5	33	4.1	77	4.8
Histopathology or Cytology	578	72.3	658	81.4	1236	76.9
Endoscopy	13	1.6	6	0.7	19	1.2
Bone marrow examination	111	13.9	93	11.5	204	12.7
Tumor marker	54	6.8	18	2.2	72	4.5
Total	800	100.0	808	100.0	1608	100.0


FIGURE 10 : DISTRIBUTION OF NEW CANCER PATIENTS BY METHOD AND GENDER: 2020



TABLE 12 DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	249	31.1	291	36.0	540	33.6
Radiation	20	2.5	69	8.5	89	5.5
Chemotherapy	174	21.8	139	17.2	313	19.5
Hormone	1	0.1	2	0.2	3	0.2
Immunotherapy	2	0.3	4	0.5	6	0.4
Interventional	28	3.5	25	3.1	53	3.3
Surgery & Radiotherapy	11	1.4	12	1.5	23	1.4
Surgery & Chemotherapy	81	10.1	87	10.8	168	10.4
Surgery & Hormone	1	0.1	1	0.1	2	0.1
Surgery & Immunotherapy	0	0.0	1	0.1	1	0.1
Surgery & Interventional	1	0.1	0	0.0	1	0.1
Radiotherapy & Chemotherapy	35	4.4	14	1.7	49	3.0
Chemotherapy & Hormone	0	0.0	3	0.4	3	0.2
Chemotherapy & Immunotherapy	39	4.9	33	4.1	72	4.5
Chemotherapy & Interventional	15	1.9	6	0.7	21	1.3
Hormone& Immunotherapy	2	0.3	0	0.0	2	0.1
Surgery & Radiotherapy & Chemotherapy	15	1.9	12	1.5	27	1.7
Surgery & Radiotherapy & Immunotherapy	1	0.1	0	0.0	1	0.1
Surgery & Chemotherapy & Hormone	1	0.1	0	0.0	1	0.1
Surgery & Chemotherapy& Immunotherapy	4	0.5	7	0.9	11	0.7
Chemotherapy & Hormone& Immunotherapy	1	0.1	2	0.2	3	0.2
Others	20	2.5	13	1.6	33	2.1
Counseling	99	12.4	87	10.8	186	11.6
Total	800	100.0	808	100.0	1608	100.0

TABLE 13

DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER : 2020

Treatment unit	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Medicine	213	26.6	172	21.3	385	23.9
General surgery	486	60.8	387	47.9	873	54.3
Ear Nose and Throat	62	7.8	46	5.7	108	6.7
Gynecologic oncology	0	0.0	119	14.7	119	7.4
Radiotherapy	17	2.1	68	8.4	85	5.3
Pediatric	8	1.0	8	1.0	16	1.0
Orthopedics	14	1.8	8	1.0	22	1.4
Total	800	100.0	808	100.0	1608	100.0

FIGURE 11 : DISTRIBUTION OF NEW CANCER PATIENTS BY TREATMENT UNIT AND GENDER : 2020






TABLE 14 DISTRIBUTION OF NEW CANCER PATIENTS BY STATUS : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Military	218	27.3	29	3.6	247	15.4
Civilian	582	72.8	779	96.4	1361	84.6
Total	800	100.0	808	100.0	1608	100.0

TABLE 15 DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	769	96.1	795	98.4	1564	97.3
Deaths	31	3.9	13	1.6	44	2.7
Total	800	100.0	808	100.0	1608	100.0

Survey: 31 December 2020

FIGURE 12 : DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP STATUS : 2020




TABLE 16

DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	1	0.5	0	0.0	1	0.4
25 – 29	1	0.5	0	0.0	1	0.4
30 – 34	1	0.5	0	0.0	1	0.4
35 – 39	3	1.4	4	13.8	7	2.8
40 – 44	5	2.3	3	10.3	8	3.2
45 – 49	7	3.2	3	10.3	10	4.0
50 – 54	10	4.6	4	13.8	14	5.7
55 – 59	35	16.1	3	10.3	38	15.4
60 – 64	43	19.7	2	6.9	45	18.2
65 – 69	33	15.1	4	13.8	37	15.0
70 – 74	28	12.8	3	10.3	31	12.6
75 – 79	24	11.0	1	3.4	25	10.1
80 – 84	15	6.9	2	6.9	17	6.9
85 +	12	5.5	0	0.0	12	4.9
Total	218	100.0	29	100.0	247	100.0

Majority of cases.

FIGURE 13 : DISTRIBUTION OF NEW MILITARY PERSONNEL CANCER PATIENTS BY AGE GROUP AND GENDER : 2020






TABLE 17 DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2020

Rank	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Major General – General	40	18.3	1	3.4	41	16.6
Major – Colonel	61	28.0	14	48.3	75	30.4
Sub Lieutenant – Captain	70	32.1	6	20.7	76	30.8
Sergeant Major ^{3rd} - Sergeant Major ^{1st}	38	17.4	4	13.8	42	17.0
Private ^{1st} class – Sergeant	8	3.7	4	13.8	12	4.9
Enlisted Soldier	1	0.5	0	0.0	1	0.4
Total	218	100.0	29	100.0	247	100.0

FIGURE 14 : DISTRIBUTION OF NEW CANCER PATIENTS BY RANK AND GENDER : 2020




TABLE 18

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
0 – 4	4	25.0	5	50.0	9	34.6
5 – 9	7	43.8	1	10.0	8	30.8
10 – 14	2	12.5	3	30.0	5	19.2
15 - 19	3	18.8	1	10.0	4	15.4
Total	16	100.0	10	100.0	26	100.0

TABLE 19

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY PRIMARY SITES : 2020

Ordinal	Primary site	Male	Female	Total	
		Number	Number	Number	Percent
1.	Adrenal gland	1	0	1	3.8
2.	Bone & articular cartilage	1	1	2	7.7
3.	Brain	3	2	5	19.2
4.	leukaemia	7	4	11	42.3
5.	Mesothelial & soft tissue	1	0	1	3.8
6.	Non-Hodgkin's lymphoma	1	0	1	3.8
7.	Ovary	0	1	1	3.8
8.	Liver & intrahepatic bile ducts	1	1	2	7.7
9.	Thyroid gland	1	1	2	7.7
Total		16	10	26	100.0


TABLE 20
DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	0	0.0	2	20.0	2	7.7
Radiation	1	6.3	1	10.0	2	7.7
Chemotherapy	7	43.8	5	50.0	12	46.2
Interventional	1	6.3	0	0.0	1	3.8
Surgery & Radiotherapy	1	6.3	0	0.0	1	3.8
Surgery & Chemotherapy	4	25.0	2	20.0	6	23.1
Surgery & Radiotherapy & Chemotherapy	1	6.3	0	0.0	1	3.8
Counseling	1	6.3	0	0.0	1	3.8
Total	16	100.0	10	100.0	26	100.0

TABLE 21
DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY METHOD AND GENDER : 2020

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	1	10.0	1	3.8
Bone marrow	7	43.8	4	40.0	11	42.3
Histopathology or Cytology	8	50.0	5	50.0	13	50.0
Tumor marker	1	6.3	0	0.0	1	3.8
Total	16	100.0	10	100.0	26	100.0

TABLE 22

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY TYPE OF EXTENSION AND GENDER : 2020

Spreading/Metastasis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	15	93.8	10	100.0	25	96.2
Distant metastasis	1	6.3	0	0.0	1	3.8
Total	16	100.0	10	100.0	26	100.0

TABLE 23

DISTRIBUTION OF NEW CHILDHOOD CANCER PATIENTS (AGE 0 - 19) BY FOLLOW UP AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	15	93.8	10	100.0	25	96.2
Deaths	1	6.3	0	0.0	1	3.8
Total	16	100.0	10	100.0	26	100.0

Survey: 31 December 2020



TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2020

Site	Sex		Stage						
			I	II	III	IV	No stage	Unknown	Total
Adrenal gland	Male		-	0	2	-	2	-	4
	Female		-	1	0	-	1	-	2
	Total	(N)	-	1	2	-	3	-	6
		(%)	-	16.7	33.3	-	50.0	-	100.0
Anus & anus canal	Male		1	-	1	2	-	-	4
	Female		1	-	0	3	-	-	4
	Total	(N)	2	-	1	5	-	-	8
		(%)	25.0	-	12.5	62.5	-	-	100.0
Bladder	Male		8	8	5	7	-	-	28
	Female		1	0	1	1	-	-	3
	Total	(N)	9	8	6	8	-	-	31
		(%)	29.0	25.8	19.4	25.8	-	-	100.0
Bone & articular cartilage	Male		3	6	0	1	-	1	11
	Female		2	2	3	1	-	0	8
	Total	(N)	5	8	3	2	-	1	19
		(%)	26.3	42.1	15.8	10.5	-	5.3	100.0
Brain	Male		-	0	-	-	20	-	20
	Female		-	1	-	-	8	-	9
	Total	(N)	-	1	-	-	28	-	29
		(%)	-	3.4	-	-	96.6	-	100.0
Breast	Male		0	3	0	0	-	0	3
	Female		50	59	46	25	-	1	181
	Total	(N)	50	62	46	25	-	1	184
		(%)	27.2	33.7	25.0	13.6	-	0.5	100.0
Cervix	Male		0	0	0	0	-	-	0
	Female		15	13	21	2	-	-	51
	Total	(N)	15	13	21	2	-	-	51
		(%)	29.4	25.5	41.2	3.9	-	-	100.0
Myelodysplastic syndromes	Male		1	-	-	-	-	-	1
	Female		0	-	-	-	-	-	0
	Total	(N)	1	-	-	-	-	-	1
		(%)	100.0	-	-	-	-	-	100.0

TABLE 24

NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2020

Site	Sex		Stage					
			I	II	III	IV	No stage	Unknown
Colon & Rectosigmoid junction & Rectum	Male		14	27	33	33	-	-
	Female		8	24	21	19	-	-
	Total	(N)	22	51	54	52	-	-
		(%)	12.3	28.5	30.2	29.1	-	-
Corpus uteri	Male		0	0	0	0	-	-
	Female		25	4	9	4	-	-
	Total	(N)	25	4	9	4	-	-
		(%)	59.5	9.5	21.4	9.5	-	-
Female genital organs	Male		0	0	-	-	-	-
	Female		1	1	-	-	-	-
	Total	(N)	1	1	-	-	-	-
		(%)	50.0	50.0	-	-	-	-
Gall bladder & unspecified parts of biliary tract	Male		1	0	1	3	-	0
	Female		0	3	1	0	-	1
	Total	(N)	1	3	2	3	-	1
		(%)	10.0	30.0	20.0	30.0	-	10.0
Hodgkin's disease	Male		2	2	5	-	-	-
	Female		1	1	1	-	-	-
	Total	(N)	3	3	6	-	-	-
		(%)	25.0	25.0	50.0	-	-	-
Hypopharynx	Male		2	1	2	-	-	-
	Female		0	0	0	-	-	-
	Total	(N)	2	1	2	-	-	-
		(%)	40.0	20.0	40.0	-	-	-
Intrathoracic organs	Male		2	3	2	0	-	-
	Female		0	4	1	1	-	-
	Total	(N)	2	7	3	1	-	-
		(%)	15.4	53.8	23.1	7.7	-	-
Male genital organs	Male		-	2	5	1	-	-
	Female		-	-	-	-	-	-
	Total	(N)	-	2	5	1	-	-
		(%)	-	25.0	62.5	12.5	-	-


TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2020

Site	Sex		Stage						
			I	II	III	IV	No stage	Unknown	Total
Non-Hodgkin's lymphoma	Male		2	8	17	26	1	-	54
	Female		7	17	8	16	-	-	48
	Total	(N)	9	25	25	42	1	-	102
		(%)	8.8	24.5	24.5	41.2	1.0	-	100.0
Esophagus	Male		-	1	8	9	-	-	18
	Female		-	-	1	1	-	-	2
	Total	(N)	-	1	9	10	-	-	20
		(%)	-	5.0	45.0	50.0	-	-	100.0
Oropharynx	Male		1	1	-	1	-	-	3
	Female		-	-	-	-	-	-	-
	Total	(N)	1	1	-	1	-	-	3
		(%)	33.3	33.3	-	33.3	-	-	100.0
Other and ill-defined digestive organs	Male		-	1	-	-	-	-	1
	Female		-	-	-	-	-	1	1
	Total	(N)	-	1	-	-	-	1	2
		(%)	-	50.0	-	-	-	50.0	100.0
Other endocrine glands and relate structures	Male		-	-	-	-	-	-	-
	Female		-	1	-	-	1	-	2
	Total	(N)	-	1	-	-	1	-	2
		(%)	-	50.0	-	-	50.0	-	100.0
Ovary	Male		-	-	-	-	-	-	-
	Female		12	4	7	4	-	-	27
	Total	(N)	12	4	7	4	-	-	27
		(%)	44.5	14.8	25.9	14.8	-	-	100.0
Pancreas	Male		1	3	1	4	-	-	9
	Female		1	7	4	8	-	-	20
	Total	(N)	2	10	5	12	-	-	29
		(%)	6.9	34.5	17.2	41.4	-	-	100.0
Prostate gland	Male		22	35	6	20	-	1	84
	Female		-	-	-	-	-	-	-
	Total	(N)	22	35	6	20	-	1	84
		(%)	26.2	41.7	7.1	23.8	-	1.2	100.0

TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2020

Site	Sex		Stage					
			I	II	III	IV	No stage	Unknown
Pyriform sinus	Male		1	1	-	-	-	-
	Female		-	-	-	-	-	-
	Total	(N)	1	1	-	-	-	-
		(%)	50.0	50.0	-	-	-	-
Liver & intrahepatic bile ducts	Male		11	34	20	18	-	-
	Female		1	14	8	9	-	-
	Total	(N)	12	48	28	27	-	-
		(%)	10.4	41.7	24.3	23.5	-	-
Skin	Male		2	6	2	2	-	-
	Female		5	4	3	1	-	-
	Total	(N)	7	10	5	3	-	-
		(%)	28.0	40.0	20.0	12.0	-	-
Small intestine	Male		1	2	0	0	-	-
	Female		-	2	1	1	-	-
	Total	(N)	1	4	1	1	-	-
		(%)	14.3	57.1	14.3	14.3	-	-
Stomach	Male		1	2	8	3	-	-
	Female		-	4	3	7	-	1
	Total	(N)	1	6	11	10	-	1
		(%)	3.4	20.7	37.9	34.5	-	3.4
Thyroid gland	Male		9	2	10	5	-	-
	Female		43	28	15	5	-	-
	Total	(N)	52	30	25	10	-	-
		(%)	44.4	25.6	21.4	8.5	-	-
Tonsil	Male		-	4	3	2	-	-
	Female		-	1	3	1	-	-
	Total	(N)	-	5	6	3	-	-
		(%)	-	35.7	42.9	21.4	-	-
Trachea, bronchus & lung	Male		9	11	22	67	-	-
	Female		12	4	8	39	-	-
	Total	(N)	21	15	30	106	-	-
		(%)	12.2	8.7	17.4	61.6	-	-



TABLE 24 NUMBER OF NEW CANCER PATIENTS STAGE AND GENDER : 2020

Site	Sex		Stage					
			I	II	III	IV	No stage	Unknown
Uterus	Male		-	-	-	-	-	-
	Female		3	-	-	-	-	3
	Total	(N)	3	-	-	-	-	3
		(%)	100	-	-	-	-	100
Without specification of site	Male		-	-	1	6	-	7
	Female		-	-	-	4	-	4
	Total	(N)	-	-	1	10	-	11
		(%)	-	-	9.1	90.9	-	100.0



DESCRIPTION OF THE LEADING SITES OF CANCERS

1. BREAST

2. COLON & RECTUM

3. TRACHEA, BRONCHUS AND LUNG

4. THYROID

5. LIVER AND INTRAHEPATIC BILE DUCTS

6. LIVER AND INTRAHEPATIC BILE DUCTS



1. BREAST CANCER

TABLE 25 TREND OF BREAST CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2009 - 2020			
Years	Number of patients		Total
	Male	Female	
2009	4	172	176
2010	2	221	223
2011	0	219	219
2012	1	291	292
2013	1	285	286
2014	0	261	261
2015	2	197	199
2016	2	198	200
2017	5	166	171
2018	4	180	184
2019	3	206	209
2020	3	181	184

BREAST


TABLE 26

DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 29	0	0.0	0	0.0	0	0.0
30 – 34	0	0.0	5	2.8	5	2.7
35 – 39	0	0.0	10	5.5	10	5.4
40 – 44	0	0.0	14	7.7	14	7.6
45 – 49	0	0.0	17	9.4	17	9.2
50 – 54	0	0.0	28	15.5	28	15.2
55 – 59	1	33.3	31	17.1	32	17.4
60 – 64	0	0.0	23	12.7	23	12.5
65 – 69	0	0.0	21	11.6	21	11.4
70 – 74	0	0.0	10	5.5	10	5.4
75 – 79	1	33.3	4	2.2	5	2.7
80 – 84	0	0.0	12	6.6	12	6.5
85 +	1	33.3	6	3.3	7	3.8
Total	3	100.0	181	100.0	184	100.0

Majority of cases.

FIGURE 15 : DISTRIBUTION OF BREAST CANCER PATIENTS BY AGE GROUP AND GENDER: 2020






BREAST

TABLE 27		DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2020				
Stage of Colon & Rectum	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	0	0.0	50	27.6	50	27.2
Stage II	3	100.0	59	32.6	62	33.7
Stage III	0	0.0	46	25.4	46	25.0
Stage IV	0	0.0	25	13.8	25	13.6
Unknown	0	0.0	1	0.6	1	0.5
Total	3	100.0	181	100.0	184	100.0

FIGURE 16 : DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY STAGE AND GENDER : 2020



BREAST

TABLE 28

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY METHOD AND GENDER : 2020


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	0	0.0	6	3.3	6	3.3
Histopathology or Cytology	3	100.0	175	96.7	178	96.7
Total	3	100.0	181	100.0	184	100.0

TABLE 29

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	2	66.7	105	58.0	107	58.2
Regional lymph nodes	1	33.3	48	26.5	49	26.6
Distant metastasis	0	0.0	28	15.5	28	15.2
Total	3	100.0	181	100.0	184	100.0

FIGURE 17 : DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY EXTENSION AND GENDER : 2020





BREAST

TABLE 30

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	1	33.3	81	44.8	82	44.6
Chemotherapy	0	0.0	30	16.6	30	16.3
Hormone	0	0.0	2	1.1	2	1.1
Surgery & Radiotherapy	0	0.0	1	0.6	1	0.5
Surgery & Chemotherapy	1	33.3	36	19.9	37	20.1
Surgery & Hormone	0	0.0	1	0.6	1	0.5
Radiotherapy & Chemotherapy	0	0.0	2	1.1	2	1.1
Chemotherapy & Hormone	0	0.0	3	1.7	3	1.6
Chemotherapy & Immunotherapy	0	0.0	7	3.9	7	3.8
Surgery & Chemotherapy & Immunotherapy	1	33.3	3	1.7	4	2.2
Chemotherapy & Hormone & Immunotherapy	0	0.0	1	0.6	1	0.5
Counseling	0	0.0	14	7.7	14	7.6
Total	3	100.0	181	100.0	184	100.0

TABLE 31

DISTRIBUTION OF NEW BREAST CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	3	100.0	180	99.4	183	99.5
Deaths	0	0.0	1	0.6	1	0.5
Total	3	100.0	181	100.0	184	100.0

Survey: 31 December 2020

2. COLON & RECTUM CANCER

TABLE 32

TREND OF COLON & RECTUM CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2009 - 2020

Years	Number of patients		Total
	Male	Female	
2009	99	65	164
2010	111	76	187
2011	123	78	201
2012	146	78	224
2013	131	87	218
2014	130	87	217
2015	120	81	201
2016	140	88	228
2017	102	67	169
2018	104	56	160
2019	132	91	223
2020	107	72	179



TRACHEA, BRONCHUS AND LUNG


TABLE 33

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 24	0	0.0	0	0.0	0	0.0
25 – 29	3	2.8	0	0.0	3	1.7
30 – 34	3	2.8	1	1.4	4	2.2
35 – 39	2	1.9	4	5.6	6	3.4
40 – 44	1	0.9	0	0.0	1	0.6
45 – 49	7	6.5	5	6.9	12	6.7
50 – 54	7	6.5	7	9.7	14	7.8
55 – 59	17	15.9	8	11.1	25	14.0
60 – 64	18	16.8	9	12.5	27	15.1
65 – 69	13	12.1	9	12.5	22	12.3
70 – 74	13	12.1	7	9.7	20	11.2
75 – 79	10	9.3	10	13.9	20	11.2
80 – 84	9	8.4	7	9.7	16	8.9
85 +	4	3.7	5	6.9	9	5.0
Total	107	100.0	72	100.0	179	100.0

Majority of cases.

FIGURE 18 : DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY AGE GROUP AND GENDER : 2020




COLON & RECTUM

TABLE 34

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER : 2020

Stage of Colon & Rectum	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	14	13.1	8	11.1	22	12.3
Stage II	27	25.2	24	33.3	51	28.5
Stage III	33	30.8	21	29.2	54	30.2
Stage IV	33	30.8	19	26.4	52	29.1
Total	107	100.0	72	100.0	179	100.0

FIGURE 19 : DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY STAGE AND GENDER : 2020





COLON & RECTUM


TABLE 35 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY METHOD AND GENDER : 2020

Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	3	2.8	3	4.2	6	3.4
Histopathology or Cytology	93	86.9	65	90.3	158	88.3
Endoscopy	11	10.3	4	5.6	15	8.4
Total	107	100.0	72	100.0	179	100.0

TABLE 36 DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	49	45.8	40	55.6	89	49.7
Regional lymph nodes	24	22.4	13	18.1	37	20.7
Distant metastasis	34	31.8	19	26.4	53	29.6
Total	107	100.0	72	100.0	179	100.0

FIGURE 20 : DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY EXTENSION AND GENDER : 2020



COLON & RECTUM

TABLE 37

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	43	40.2	31	43.1	74	41.3
Chemotherapy	22	20.6	12	16.7	34	19.0
Surgery & Chemotherapy	28	26.2	20	27.8	48	26.8
Radiotherapy & Chemotherapy	1	0.9	1	1.4	2	1.1
Chemotherapy & Immunotherapy	1	0.9	0	0.0	1	0.6
Hormone& Immunotherapy	1	0.9	0	0.0	1	0.6
Surgery & Radiotherapy& Chemotherapy	2	1.9	1	1.4	3	1.7
Surgery & Chemotherapy& Immunotherapy	0	0.0	1	1.4	1	0.6
Others	0	0.0	2	2.8	2	1.1
Counseling	9	8.4	4	5.6	13	7.3
Total	107	100.0	72	100.0	179	100.0

TABLE 38

DISTRIBUTION OF NEW COLON & RECTUM CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	103	96.3	69	95.8	172	96.1
Deaths	4	3.7	3	4.2	7	3.9
Total	107	100.0	72	100.0	179	100.0

Survey: 31 December 2020



3. TRACHEA, BRONCHUS AND LUNG

TABLE 39 TREND OF TRACHEA, BRONCHUS AND LUNG CANCER IN PHRAMONGKUTKLAO HOSPITAL : 2009 – 2020			
Years	Number of patients		Total
	Male	Female	
2009	114	58	172
2010	104	61	165
2011	142	68	210
2012	146	69	215
2013	145	75	220
2014	134	84	218
2015	115	65	180
2016	119	79	198
2017	118	73	191
2018	119	81	200
2019	142	70	212
2020	109	63	172

TRACHEA, BRONCHUS AND LUNG


TABLE 40

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 19	0	0.0	0	0.0	0	0.0
20 – 24	2	1.8	1	1.6	3	1.7
25 – 29	0	0.0	1	1.6	1	0.6
30 – 34	0	0.0	0	0.0	0	0.0
35 – 39	1	0.9	1	1.6	2	1.2
40 – 44	2	1.8	4	6.3	6	3.5
45 – 49	8	7.3	5	7.9	13	7.6
50 – 54	4	3.7	3	4.8	7	4.1
55 – 59	13	11.9	14	22.2	27	15.7
60 – 64	14	12.8	7	11.1	21	12.2
65 – 69	26	23.9	10	15.9	36	20.9
70 – 74	13	11.9	6	9.5	19	11.0
75 – 79	17	15.6	7	11.1	24	14.0
80 – 84	6	5.5	3	4.8	9	5.2
85 +	3	2.8	1	1.6	4	2.3
Total	109	100.0	63	100.0	172	100.0

Majority of cases.

FIGURE 21 : DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY AGE GROUP AND GENDER : 2020






TRACHEA, BRONCHUS AND LUNG

TABLE 41

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2020

Stage of Trachea, Bronchus and Lung	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	9	8.3	12	19.0	21	12.2
Stage II	11	10.1	4	6.3	15	8.7
Stage III	22	20.2	8	12.7	30	17.4
Stage IV	67	61.5	39	61.9	106	61.6
Total	109	100.0	63	100.0	172	100.0

FIGURE 22 : DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY STAGE AND GENDER : 2020



TRACHEA, BRONCHUS AND LUNG

TABLE 42

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY METHOD AND GENDER : 2020


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Endoscopy & Radiology	10	9.2	2	3.2	12	7.0
Histopathology or Cytology	99	90.8	61	96.8	160	93.0
Total	109	100.0	63	100.0	172	100.0

TABLE 43

DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	35	32.1	23	36.5	58	33.7
Direct extension	1	0.9	0	0.0	1	0.6
Regional lymph nodes	15	13.8	6	9.5	21	12.2
Distant metastasis	58	53.2	34	54.0	92	53.5
Total	109	100.0	63	100.0	172	100.0

FIGURE 23 : DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY EXTENSION AND GENDER : 2020





TRACHEA, BRONCHUS AND LUNG

TABLE 44
DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	31	28.4	23	36.5	54	31.4
Radiation	3	2.8	4	6.3	7	4.1
Chemotherapy	21	19.3	11	17.5	32	18.6
Surgery & Radiotherapy	1	0.9	1	1.6	2	1.2
Surgery & Chemotherapy	8	7.3	5	7.9	13	7.6
Radiotherapy & Chemotherapy	8	7.3	1	1.6	9	5.2
Chemotherapy & Immunotherapy	2	1.8	1	1.6	3	1.7
Surgery & Radiotherapy& Chemotherapy	0	0.0	4	6.3	4	2.3
Surgery & Radiotherapy & Immunotherapy	1	0.9	0	0.0	1	0.6
Surgery & Chemotherapy& Immunotherapy	1	0.9	0	0.0	1	0.6
Chemotherapy & Hormone& Immunotherapy	0	0.0	1	1.6	1	0.6
Others	1	0.9	0	0.0	1	0.6
Counseling	32	29.4	12	19.0	44	25.6
Total	109	100.0	63	100.0	172	100.0

TABLE 45
DISTRIBUTION OF NEW TRACHEA, BRONCHUS AND LUNG CANCER PATIENTS BY TREATMENT FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	104	95.4	63	100.0	167	97.1
Deaths	5	4.6	0	0.0	5	2.9
Total	109	100.0	63	100.0	172	100.0

Survey: 31 December 2020

4. THYROID


TABLE 46

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 14	0	0.0	0	0.0	0	0.0
15 – 19	1	3.8	1	1.1	2	1.7
20 – 24	0	0.0	4	4.4	4	3.4
25 – 29	1	3.8	6	6.6	7	6.0
30 – 34	1	3.8	12	13.2	13	11.1
35 – 39	1	3.8	18	19.8	19	16.2
40 – 44	4	15.4	9	9.9	13	11.1
45 – 49	5	19.2	13	14.3	18	15.4
50 – 54	1	3.8	7	7.7	8	6.8
55 – 59	3	11.5	5	5.5	8	6.8
60 – 64	3	11.5	5	5.5	8	6.8
65 – 69	5	19.2	4	4.4	9	7.7
70 – 74	1	3.8	4	4.4	5	4.3
75 – 79	0	0.0	2	2.2	2	1.7
80 – 84	0	0.0	1	1.1	1	0.9
Total	26	100.0	91	100.0	117	100.0

Majority of case.

FIGURE 24 : DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY AGE GROUP AND GENDER : 2020






THYROID

TABLE 47

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY STAGE AND GENDER : 2020

Stage of Thyroid	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	9	34.6	43	47.3	52	44.4
Stage II	2	7.7	28	30.8	30	25.6
Stage III	10	38.5	15	16.5	25	21.4
Stage IV	5	19.2	5	5.5	10	8.5
Total	26	100.0	91	100.0	117	100.0

FIGURE 25 : DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY STAGE AND GENDER: 2020



THYROID

TABLE 48

DISTRIBUTION OF THYROID CANCER PATIENTS BY METHOD AND GENDER : 2020


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Radiology	1	3.8	3	3.3	4	3.4
Histopathology or Cytology	25	96.2	88	96.7	113	96.6
Total	26	100.0	91	100.0	117	100.0

TABLE 49

DISTRIBUTION OF THYROID CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	14	53.8	74	81.3	88	75.2
Direct extension	1	3.8	0	0.0	1	0.9
Regional lymph nodes	8	30.8	13	14.3	21	17.9
Distant metastasis	3	11.5	4	4.4	7	6.0
Total	26	100.0	91	100.0	117	100.0

FIGURE 26 : DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY EXTENSION AND GENDER : 2020





THYROID

TABLE 50

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020


Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	12	46.2	23	25.3	35	29.9
Radiation	9	34.6	51	56.0	60	51.3
Surgery & Radiotherapy	1	3.8	7	7.7	8	6.8
Surgery & Chemotherapy	1	3.8	0	0.0	1	0.9
Others	1	3.8	0	0.0	1	0.9
Counseling	2	7.7	10	11.0	12	10.3
Total	26	100.0	91	100.0	117	100.0

TABLE 51

DISTRIBUTION OF NEW THYROID CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	25	96.2	90	98.9	115	98.3
Deaths	1	3.8	1	1.1	2	1.7
Total	26	100.0	91	100.0	117	100.0

Survey: 31 December 2020



5. LIVER AND INTRAHEPATIC BILE DUCTS


TABLE 52

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 04	1	1.2	1	3.1	2	1.7
05 – 09	0	0.0	0	0.0	0	0.0
10 – 14	0	0.0	0	0.0	0	0.0
15 – 19	0	0.0	0	0.0	0	0.0
20 – 24	0	0.0	0	0.0	0	0.0
25 – 29	0	0.0	0	0.0	0	0.0
30 – 34	1	1.2	0	0.0	1	0.9
35 – 39	3	3.6	0	0.0	3	2.6
40 – 44	7	8.4	1	3.1	8	7.0
45 – 49	1	1.2	0	0.0	1	0.9
50 – 54	11	13.3	1	3.1	12	10.4
55 – 59	15	18.1	7	21.9	22	19.1
60 – 64	16	19.3	5	15.6	21	18.3
65 – 69	12	14.5	2	6.3	14	12.2
70 – 74	6	7.2	4	12.5	10	8.7
75 – 79	5	6.0	5	15.6	10	8.7
80 – 84	2	2.4	2	6.3	4	3.5
85+	3	3.6	4	12.5	7	6.1
Total	83	100.0	32	100.0	115	100.0

Majority of cases.

FIGURE 27 : DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY AGE GROUP AND GENDER : 2020






LIVER AND INTRAHEPATIC BILE DUCTS

TABLE 53

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2020

Stage	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	11	13.3	1	3.1	12	10.4
Stage II	34	41.0	14	43.8	48	41.7
Stage III	20	24.1	8	25.0	28	24.3
Stage IV	18	21.7	9	28.1	27	23.5
Total	83	100.0	32	100.0	115	100.0

FIGURE 28 : DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY STAGE AND GENDER : 2020



LIVER AND INTRAHEPATIC BILE DUCTS

TABLE 54

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY METHOD AND GENDER : 2020


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Endoscopy & Radiology	10	12.0	1	3.1	11	9.6
Histopathology or Cytology	20	24.1	14	43.8	34	29.6
Tumor marker	53	63.9	17	53.1	70	60.9
Total	83	100.0	32	100.0	115	100.0

TABLE 55

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY EXTENSION AND GENDER : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	66	79.5	23	71.9	89	77.4
Direct extension	0	0.0	1	3.1	1	0.9
Regional lymph nodes	1	1.2	1	3.1	2	1.7
Distant metastasis	16	19.3	7	21.9	23	20.0
Total	83	100.0	32	100.0	115	100.0

FIGURE 29 : DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS





LIVER AND INTRAHEPATIC BILE DUCTS

TABLE 56

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY TREATMENT MODALITIES AND GENDER : 2020

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	16	19.3	6	18.8	22	19.1
Radiation	1	1.2	0	0.0	1	0.9
Chemotherapy	23	27.7	2	6.3	25	21.7
Immunotherapy	1	1.2	0	0.0	1	0.9
Interventional	26	31.3	17	53.1	43	37.4
Surgery & Chemotherapy	0	0.0	1	3.1	1	0.9
Surgery & Interventional	1	1.2	0	0.0	1	0.9
Radiotherapy & Chemotherapy	0	0.0	1	3.1	1	0.9
Chemotherapy & Interventional	15	18.1	4	12.5	19	16.5
Surgery & Radiotherapy& Chemotherapy	0	0.0	1	3.1	1	0.9
Total	83	100.0	32	100.0	115	100.0

TABLE 57

DISTRIBUTION OF NEW LIVER AND INTRAHEPATIC BILE DUCTS CANCER PATIENTS BY FOLLOW UP STATUS AND GENDER : 2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	81	97.6	31	96.9	112	97.4
Deaths	2	2.4	1	3.1	3	2.6
Total	83	100.0	32	100.0	115	100.0

Survey: 31 December 2020

6. NON-HODGKIN'S LYMPHOMA


TABLE 58

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY AGE GROUP IN MALE : 2020

Age group	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
00 – 09	1	1.9	0	0.0	1	1.0
10 – 14	0	0.0	0	0.0	0	0.0
15 – 19	0	0.0	0	0.0	0	0.0
20 – 24	1	1.9	1	2.1	2	2.0
25 – 29	2	3.7	3	6.3	5	4.9
30 – 34	4	7.4	3	6.3	7	6.9
35 – 39	0	0.0	2	4.2	2	2.0
40 – 44	3	5.6	2	4.2	5	4.9
45 – 49	4	7.4	3	6.3	7	6.9
50 – 54	4	7.4	6	12.5	10	9.8
55 – 59	2	3.7	5	10.4	7	6.9
60 – 64	11	20.4	7	14.6	18	17.6
65 – 69	2	3.7	4	8.3	6	5.9
70 – 74	14	25.9	4	8.3	18	17.6
75 – 79	4	7.4	3	6.3	7	6.9
80 – 84	0	0.0	2	4.2	2	2.0
85+	2	3.7	3	6.3	5	4.9
Total	54	100.0	48	100.0	102	100.0

Majority of cases.

FIGURE 30 : DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY AGE GROUP
IN MALE: 2020






PROSTATE

TABLE 59

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY STAGE IN MALE: 2020

Stage of Prostate	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Stage I	2	3.7	7	14.6	9	8.8
Stage II	8	14.8	17	35.4	25	24.5
Stage III	17	31.5	8	16.7	25	24.5
Stage IV	26	48.1	16	33.3	42	41.2
No stage	1	1.9	0	0.0	1	1.0
Total	54	100.0	48	100.0	102	100.0

FIGURE 31 : DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY STAGE IN MALE : 2020



NON-HODGKIN'S LYMPHOMA

TABLE 60

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY METHOD IN MALE : 2020


Method of diagnosis	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Histopathology or Cytology	1	1.9	4	8.3	5	4.9
Bone marrow examination	53	98.1	44	91.7	97	95.1
Total	54	100.0	48	100.0	102	100.0

TABLE 61

DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY EXTENSION IN MALE : 2020

Extension	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Localized	38	70.4	40	83.3	78	76.5
Regional lymph nodes	4	7.4	3	6.3	7	6.9
Distant metastasis	12	22.2	5	10.4	17	16.7
Total	54	100.0	48	100.0	102	100.0

FIGURE 32 : DISTRIBUTION OF NEW NON-HODGKIN'S LYMPHOMA CANCER PATIENTS BY EXTENSION IN MALE: 2020





NON-HODGKIN'S LYMPHOMA

Treatment modality	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Surgery	3	5.6	0	0.0	3	2.9
Chemotherapy	25	46.3	27	56.3	52	51.0
Surgery & Chemotherapy	1	1.9	2	4.2	3	2.9
Radiotherapy & Chemotherapy	0	0.0	1	2.1	1	1.0
Chemotherapy & Immunotherapy	23	42.6	13	27.1	36	35.3
Surgery & Chemotherapy & Immunotherapy	0	0.0	1	2.1	1	1.0
Others	1	1.9	3	6.3	4	3.9
Counseling	1	1.9	1	2.1	2	2.0
Total	54	100.0	48	100.0	102	100.0

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	53	98.1	46	95.8	99	97.1
Deaths	1	1.9	2	4.2	3	2.9
Total	54	100.0	48	100.0	102	100.0

Survey: 31 December 2020

● MALE ●

TABLE 64 DISTRIBUTION OF NEW CANCER IN MALE BY AGE - GROUP : 2020

ICD_10	Site	Age Total	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			- 4	- 9	- 14	- 19	- 24	- 29	- 34	- 39	- 44	- 49	- 54	- 59	- 64	- 69	- 74	- 79	- 84	+
C00-C08	Oral cavity	17	0	0	0	0	0	0	1	1	2	2	2	4	2	0	1	1	1	0
C01,C05,C10	Oropharynx	10	0	0	0	0	0	0	0	0	0	0	0	3	2	3	0	1	1	0
C09	Tonsil	9	0	0	0	0	0	0	0	0	2	0	1	2	1	0	0	1	1	1
C11	Nasopharynx	16	0	0	0	0	1	0	0	0	2	5	0	4	1	1	1	1	0	0
C12-C13	Hypopharynx	7	0	0	0	0	0	0	0	0	0	0	1	3	1	1	1	0	0	0
C14	Pharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Esophagus	18	0	0	0	0	0	1	0	0	2	5	2	1	2	2	0	2	1	0
C16	Stomach	14	0	0	0	0	0	0	0	0	0	1	2	4	5	2	0	0	0	0
C17	Small intestine	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	0	0
C18-C20	Colon and Rectum	107	0	0	0	0	0	3	3	2	1	7	7	17	18	13	13	10	9	4
C21	Anus	4	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	0	2
C22	Liver and Bile ducts	83	1	0	0	0	0	0	1	3	7	1	11	15	16	12	6	5	2	3
C23-C24	Gallbladder	5	0	0	0	0	0	0	0	0	0	0	2	0	1	0	1	0	1	0
C25	Pancreas	9	0	0	0	0	0	0	0	1	0	0	1	1	1	5	0	0	0	0
C30-C31	Nose, sinuses etc	2	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0
C32	Larynx	20	0	0	0	0	0	0	0	0	0	1	1	7	3	4	1	2	1	0
C33-C34	Trachea, bronchus, lung	109	0	0	0	0	2	0	0	1	2	8	4	13	14	26	13	17	6	3
C37-C39	Other thoracic organs	6	0	0	0	0	2	0	1	0	0	1	0	0	1	0	0	1	0	0
C40-C41	Bone & joints	11	0	0	1	0	0	0	0	2	0	2	1	1	0	1	1	0	2	0
C43-C44	Melanoma of skin	12	0	0	0	0	0	0	1	2	0	2	2	1	0	1	2	0	0	1
C45-C49	Mesothelioma	14	0	0	0	1	0	0	0	1	0	2	1	1	3	2	1	2	0	0
C50	Breast	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1
C60, C62-C63	Male genital organs	9	0	0	0	0	0	1	0	0	0	0	1	3	1	1	1	0	1	0
C61	Prostate	84	0	0	0	0	0	0	0	0	0	0	1	3	14	19	19	20	5	3
C64-C66	Kidney & Ureter	29	0	0	0	0	0	0	0	1	3	4	6	4	4	5	2	0	0	0
C67	Bladder	28	0	0	0	0	0	0	0	1	0	1	2	4	0	5	4	2	6	3
C69-C70	Eye & Meninges	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C71-C72	Brain	20	1	1	0	1	0	0	1	2	2	3	2	4	2	1	0	0	0	0
C73	Thyroid gland	26	0	0	0	1	0	1	1	1	4	5	1	3	3	5	1	0	0	0
C74	Adrenal gland	4	0	1	0	0	0	0	0	0	0	0	1	1	0	0	0	1	0	0
C75	Other endocrine glands	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C80	Without unspecified	7	0	0	0	0	0	0	0	0	0	0	1	1	4	0	0	0	0	1
C81	Hodgkin's disease	9	0	0	0	0	0	4	1	0	1	2	1	0	0	0	0	0	0	0
C82 -C85,	Non-Hodgkin lymphoma	54	0	1	0	0	1	2	4	0	3	4	4	2	11	2	14	4	0	2
C90	Multiple myeloma	15	0	0	0	0	0	1	0	1	0	1	0	2	3	1	3	2	0	1
C91-C95	Leukemia	35	2	4	1	0	2	0	2	4	3	0	2	1	4	4	2	2	2	0
Total		800	4	7	2	3	8	14	16	23	34	57	62	107	117	117	89	75	40	25



● FEMALE ●

TABLE 65 DISTRIBUTION OF NEW CANCER IN FEMALE BY AGE - GROUP : 2020

ICD_10	Sites	Age Total	0	5	10	15	20	25	30	35	40	45	50	55	60	65	70	75	80	85
			- 4	- 9	- 14	- 19	- 24	- 29	- 34	- 39	- 44	- 49	- 54	- 59	- 64	- 69	- 74	- 79	- 84	+
C00-C08	Oral cavity	13	0	0	0	0	0	1	0	1	2	1	1	1	1	3	0	1	1	0
C01,C05,C10	Oropharynx	6	0	0	0	0	0	0	0	0	0	1	0	1	2	2	0	0	0	0
C11	Nasopharynx	7	0	0	0	0	0	0	0	3	1	0	1	0	1	0	1	0	0	0
C12-C13	Hypopharynx	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C14	Pharynx	2	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0
C16	Stomach	15	0	0	0	0	0	0	0	0	2	1	1	3	3	1	1	0	2	1
C17	Small intestine	4	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0	2	0
C18-C20	Colon and Rectum	72	0	0	0	0	0	0	1	4	0	5	7	8	9	9	7	10	7	5
C21	Anus	4	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0	0	1	0
C22	Liver and Bile ducts	32	1	0	0	0	0	0	0	0	1	0	1	7	5	2	4	5	2	4
C23-C24	Gallbladder	5	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0	0	0	2
C25	Pancreas	20	0	0	0	0	1	0	0	2	0	0	0	4	2	1	4	1	3	2
C26	Other and ill-defined digestive organs	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C30-C31	Nose, sinuses etc	3	0	0	0	0	0	0	1	0	0	1	0	0	0	0	0	1	0	0
C32	Larynx	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C33-C34	Trachea, bronchus, lung	63	0	0	0	0	1	1	0	1	4	5	3	14	7	10	6	7	3	1
C37-C39	Other thoracic organs	6	0	0	0	0	0	0	0	1	1	0	1	2	0	0	1	0	0	0
C40-C41	Bone	8	1	0	0	0	0	0	1	0	0	1	2	2	0	0	1	0	0	0
C43-C44	Melanoma of skin	13	0	0	0	0	0	1	0	1	0	0	0	2	1	0	3	1	0	4
C45-C49	Connective and soft tissue	6	0	0	0	0	0	0	1	0	1	0	0	1	1	0	2	0	0	0
C50	Breast	181	0	0	0	0	0	0	5	10	14	17	28	31	23	21	10	4	12	6
C51-C52, C57	Female genital organs	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	0
C53	Cervix uteri	51	0	0	0	0	1	5	3	5	5	5	10	4	8	1	2	1	0	1
C54	Corpus uteri	42	0	0	0	0	0	0	2	1	3	1	8	8	3	7	6	2	0	1
C55	Uterus	3	0	0	0	0	0	0	0	0	1	0	1	0	0	1	0	0	0	0
C56	Ovary	27	0	0	1	0	2	1	2	2	3	3	2	4	2	2	2	0	1	0
C64-C66	Kidney & Ureter	12	0	0	0	0	0	0	0	0	0	1	1	3	2	1	0	1	0	3
C67	Bladder	3	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	0
C69-C70	Eye & Meninges	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
C71-C72	Brain	9	1	1	0	0	0	1	0	1	1	1	1	2	0	0	0	0	0	0
C73	Thyroid gland	91	0	0	0	1	4	6	12	18	9	13	7	5	5	4	4	2	1	0
C80	Without unspecified	8	0	0	0	0	0	0	0	0	1	1	3	0	0	1	1	0	1	0
C81	Hodgkin's disease	3	0	0	0	0	0	0	2	0	0	0	1	0	0	0	0	0	0	0
C82 -C85	Non-Hodgkin lymphoma	48	0	0	0	0	1	3	3	2	2	3	6	5	7	4	4	3	2	3
C90	Multiple myeloma	21	0	0	0	0	0	0	0	1	1	3	2	3	2	1	4	2	1	1
C91-C95	Leukaemia	26	2	0	2	0	0	2	1	1	5	1	2	2	3	0	1	2	2	0
Total		808	5	1	3	1	10	22	34	55	57	66	91	115	88	73	65	46	42	34

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C00-C08	Lip & Oral cavity		16	12	28
C020	8071/6	Squamous cell carcinoma, keratinizing, metastatic, NOS	1	0	1
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	4	2	6
C021	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	1	2	3
C023	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C029	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
C041	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
C060	8070/3	Squamous cell carcinoma, NOS	1	0	1
C0613	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C07	8000/3	Neoplasm, malignat	1	0	1
C080	8010/3	Carcinoma, NOS	1	0	1
C089	8430/3	Mucoepidermoid carcinoma	1	0	1
	8941/6	Carcinoma in pleomorphic adenoma, metastatic	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8550/3	Acinar cell carcinoma	0	1	1
C09	Tonsil		9	4	13
C090	8010/3	Carcinoma, NOS	1	0	1
C099	8070/3	Squamous cell carcinoma, NOS	6	1	7
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	2	1	3
C01, C05, C10	Oropharynx etc.		8	2	10
C01	8070/3	Squamous cell carcinoma, NOS	4	0	4
C051	8070/3	Squamous cell carcinoma, NOS	1	1	2
C103	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C109	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
C11	Nasopharynx		12	3	15
C110	8020/3	Carcinoma, undifferentiated, NOS	1	0	1
C111	8070/3	Squamous cell carcinoma, NOS	5	0	5
	8071/3	Squamous cell carcinoma, keratinizing, NOS	3	1	4
	8010/6	Carcinoma, metastatic, NOS	0	1	1
C119	8010/3	Carcinoma, NOS	3	1	4



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C12	Pyriform sinus		5	4	9
C12	8010/6	Carcinoma, metastatic, NOS	2	0	2
	8020/3	Carcinoma, undifferentiated, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	1	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	1	2
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C13	Hypopharynx		3	0	3
C130	8070/3	Squamous cell carcinoma, NOS	2	0	2
C139	8070/3	Squamous cell carcinoma, NOS	1	0	1
C15	Esophagus		15	1	16
C150	8070/3	Squamous cell carcinoma, NOS	3	0	3
C151	8070/6	Squamous cell carcinoma, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	5	0	5
C153	8900/3	Rhabdomyosarcoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C154	8070/3	Squamous cell carcinoma, NOS	1	0	1
C155	8070/3	Squamous cell carcinoma, NOS	2	0	2
C159	8070/3	Squamous cell carcinoma, NOS	1	1	2
C16	Stomach		11	7	18
C160	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
C161	8140/3	Adenocarcinoma, NOS	3	1	4
	8140/3	Adenocarcinoma, NOS	1	1	2
C162	8936/3	Gastrointestinal stromal sarcoma	0	1	1
	8010/3	Carcinoma, NOS	1	0	1
C163	8140/3	Adenocarcinoma, NOS	3	0	3
	8140/3	Adenocarcinoma, NOS	2	0	2
C164	8140/3	Adenocarcinoma, NOS	0	1	1
C169	8010/3	Carcinoma, NOS	0	2	2
C17	Small intestine		6	11	17
C170	8140/3	Adenocarcinoma, NOS	2	4	6
	8140/3	Adenocarcinoma, NOS	0	1	1
	8336/3	Hyalinizing trabecular adenoma	0	2	2
	8490/3	Signet ring carcinoma	1	0	1
	8336/3	Hyalinizing trabecular adenoma	1	0	1
C171	8336/6	Hyalinizing trabecular adenoma	0	1	1
	8336/3	Hyalinizing trabecular adenoma	0	3	3
C179	8890/3	Leiomyosarcoma, NOS	1	0	1
	8336/3	Hyalinizing trabecular adenoma	1	0	1

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C18-C20	Colon & Rectosigmoid junction & Rectum		93	62	155
C180	8010/3	Carcinoma, NOS	1	0	1
C181	8140/3	Adenocarcinoma, NOS	1	2	3
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C182	8140/3	Adenocarcinoma, NOS	7	2	9
C183	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	5	1	6
C184	8140/3	Adenocarcinoma, NOS	2	4	6
C185	8140/3	Adenocarcinoma, NOS	1	2	3
C186	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	3	2	5
C187	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	29	16	45
C189	8140/6	Adenocarcinoma, metastatic, NOS	5	2	7
	8480/3	Signet ring carcinoma	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
C19	8140/3	Adenocarcinoma, NOS	5	4	9
	8140/6	Adenocarcinoma, metastatic, NOS	2	1	3
	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C20	8140/6	Adenocarcinoma, metastatic, NOS	1	2	3
	8140/3	Adenocarcinoma, NOS	26	20	46
C21	Anus & Anus canal		5	7	12
C210	8140/6	Adenocarcinoma, metastatic, NOS	2	4	6
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C211	8140/3	Adenocarcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	3	4
C22	Liver & Intrahepatic bile ducts		27	17	44
C220	8806/3	Desmoplastic small round cell tumor	0	1	1
	8010/3	Carcinoma, NOS	6	0	6
C221	8010/6	Carcinoma, metastatic, NOS	4	1	5
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	2	2
	8170/3	Hepatocellular carcinoma, NOS	12	3	15
	8170/6	Hepatocellular carcinoma, metastatic, NOS	1	1	2
	8010/6	Carcinoma, metastatic, NOS	0	1	1
C222	8140/3	Adenocarcinoma, NOS	2	2	4
	8160/3	Bile duct adenoma	2	1	3
	8170/3	Hepatocellular carcinoma, NOS	0	1	1
	8970/3	hepatoblastoma	0	1	1
C227	8140/3	Adenocarcinoma, NOS	0	1	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C229	8140/3	Adenocarcinoma, NOS	0	1	1
C23-C24	Gall bladder & Unspecified parts of biliary tract		5	3	8
C23	8170/3	Hepatocellular carcinoma, NOS	1	0	1
	8170/6	Hepatocellular carcinoma, metastatic, NOS	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
C240	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/3	Adenocarcinoma, NOS	1	1	2
C241	8010/3	Carcinoma, NOS	1	0	1
C25	Pancreas		7	11	18
C250	8140/3	Adenocarcinoma, NOS	1	1	2
	8010/3	Carcinoma, NOS	1	0	1
C251	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	2	3	5
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	9591/6	Malignant lymphoma, non - Hodgkin, metastatic, NOS	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
C252	8140/3	Adenocarcinoma, NOS	0	2	2
C253	8010/6	Carcinoma, metastatic, NOS	1	0	1
C259	8140/3	Adenocarcinoma, NOS	0	1	1
	9220/3	Chondrosarcoma, NOS	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
C30-C31	Nasal cavity & Accessory sinuses		2	5	7
C300	8140/3	Adenocarcinoma, NOS	1	2	3
	8070/3	Squamous cell carcinoma, NOS	0	2	2
C310	8144/3	Adenocarcinoma, intestinal type	1	0	1
	8720/3	Malignant melanoma, NOS	0	1	1
C32	Larynx		11	1	12
C320	8070/3	Squamous cell carcinoma, NOS	6	1	7
C321	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	4	0	4
C33-C34	Trachea, Bronchus & Lung		72	42	114
C340	8070/6	Squamous cell carcinoma, metastatic, NOS	2	0	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	3	0	3
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	2	0	2
	8072/6	Squamous cell carcinoma, large cell, nonkeratinizing, metastatic, NOS	1	0	1
	8010/3	Carcinoma, NOS	2	2	4
C341	8140/3	Adenocarcinoma, NOS	0	1	1
	8046/3	Non-small cell carcinoma	4	3	7
	8046/6	Non-small cell carcinoma, metastatic	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	6	5	11

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C342	8140/6	Adenocarcinoma, metastatic, NOS	1	1	2
	8430/3	Mucoepidermoid carcinoma	1	0	1
	9364/3	Peripheral neuroectodermal tumor	1	0	1
	8010/3	Carcinoma, NOS	7	4	11
	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8046/3	Non-small cell carcinoma	6	2	8
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8070/3	Squamous cell carcinoma, NOS	3	0	3
	8140/3	Adenocarcinoma, NOS	6	6	12
C343	8140/6	Adenocarcinoma, metastatic, NOS	3	1	4
	8010/3	Carcinoma, NOS	1	0	1
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8046/3	Non-small cell carcinoma	0	2	2
	8046/6	Non-small cell carcinoma, metastatic	1	0	1
	8140/3	Adenocarcinoma, NOS	3	0	3
C349	8010/3	Carcinoma, NOS	2	2	4
	8046/3	Non-small cell carcinoma	0	4	4
	8046/6	Non-small cell carcinoma, metastatic	1	0	1
	8140/3	Adenocarcinoma, NOS	6	3	9
	8140/6	Adenocarcinoma, metastatic, NOS	1	0	1
	8010/3	Carcinoma, NOS	5	4	9
C37-C38	Intrathoracic organs		43	25	68
C37	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8041/3	Adenocarcinoma, NOS	1	0	1
	8046/3	Non-small cell carcinoma	15	3	18
	8046/6	Non-small cell carcinoma, metastatic	1	1	2
	8070/3	Squamous cell carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	16	12	28
	8140/6	Adenocarcinoma, metastatic, NOS	2	2	4
	8240/3	Carcinoid tumor, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C381	8010/3	Carcinoma, NOS	0	1	1
	8580/3	Thymoma, malignant, NOS	0	1	1
	8581/3	Thymoma, type A, malignant	2	0	2
	8582/3	Thymoma, type AB, malignant	0	1	1
	8583/3	Thymoma, type B1, malignant	0	1	1
	8584/3	Thymoma, type B2, malignant	0	1	1
C384	9064/3	Germinoma	1	0	1
	9064/6	Germinoma, metastatic	1	0	1
	9071/6	Yolk sac tumor	1	0	1
	8140/3	Adenocarcinoma, NOS	0	1	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C40-C41	Bone & Articular cartilage		8	6	14
C400	8140/3	Adenocarcinoma, NOS	0	1	1
C402	9220/3	Chondrosarcoma, NOS	1	0	1
	8071/3	Squamous cell carcinoma, keratinizing, NOS	1	0	1
C409	9040/3	Synovial sarcoma, NOS	1	0	1
	9180/3	Osteosarcoma, NOS	0	2	2
	9220/3	Chondrosarcoma, NOS	1	1	2
	9260/3	Ewing sarcoma	1	0	1
	9732/3	Multiple myeloma	0	1	1
C410	8070/3	Squamous cell carcinoma, NOS	1	0	1
C414	8010/3	Carcinoma, NOS	1	0	1
C419	9220/3	Chondrosarcoma, NOS	1	0	1
	8801/3	Spindle cell sarcoma	0	1	1
C43-C44	Skin		11	8	19
C434	9250/6	Giant cell tumor of bone, NOS	1	0	1
	8720/3	Malignant melanoma, NOS	0	1	1
C436	8720/3	Malignant melanoma, NOS	0	1	1
C437	8720/3	Malignant melanoma, NOS	2	0	2
C439	8070/3	Squamous cell carcinoma, NOS	0	1	1
C441	8720/3	Malignant melanoma, NOS	1	2	3
	8410/3	Sebaceous adenocarcinoma	1	0	1
C443	8010/3	Carcinoma, NOS	0	1	1
C445	8070/3	Squamous cell carcinoma, NOS	1	2	3
	8090/3	Basal cell carcinoma, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	1	0	1
C447	8070/3	Squamous cell carcinoma, NOS	2	0	2
C449	8010/3	Carcinoma, NOS	1	0	1
C45 – C49	Mesothelial & Soft tissue		13	8	21
C480	8070/3	Squamous cell carcinoma, NOS	0	2	2
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	1	1
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
	8090/3	Basal cell carcinoma, NOS	1	1	2
	8850/6	Liposarcoma, metastatic, NOS	1	0	1
C482	8896/3	Myxoid leiomyosarcoma	0	1	1
	8140/3	Adenocarcinoma, NOS	0	1	1
C490	8720/3	Malignant melanoma, NOS	1	0	1
C491	8801/3	Spindle cell sarcoma	0	1	1
C492	8805/3	Undifferentiated sarcoma	1	0	1
	8850/3	Liposarcoma, NOS	1	0	1

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C493	8850/6	Liposarcoma, metastatic, NOS	1	0	1
	8852/3	Myxoid liposarcoma	1	0	1
	9150/3	Hemangiopericytoma, malignant	0	1	1
	9260/3	Ewing sarcoma	1	0	1
	8090/6	Basal cell carcinoma, metastatic, NOS	1	0	1
C494	8720/3	Malignant melanoma, NOS	1	0	1
	8890/3	Liomyosarcoma, NOS	1	0	1
	8772/6	Spindle cell melanoma, metastatic, NOS	1	0	1
C50	Breast		1	69	70
C500	8850/3	Liposarcoma, NOS	1	0	1
	8010/3	Carcinoma, NOS	0	1	1
C501	8500/3	Infiltrating duct carcinoma, NOS	0	18	18
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
	8575/3	Metaplastic carcinoma	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	8	8
C502	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
	8253/3	Bronchiolo-alveolar carcinoma, mucinous	0	1	1
C503	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
	8520/3	Lobular carcinoma, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	4	4
C504	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	1	1
	8010/3	Carcinoma, NOS	0	1	1
C505	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	7	7
	8500/3	Infiltrating duct carcinoma, NOS	0	5	5
C508	9680/6	Malignant lymphoma, large B-cell, diffuse, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	0	1	1
C509	8010/3	Carcinoma, NOS	0	11	11
C51,C52,C57	Female genital organs		4	121	125
C510	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8050/3	Papillary carcinoma, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8500/3	Infiltrating duct carcinoma, NOS	2	84	86
	8500/6	Infiltrating duct carcinoma, metastatic, NOS	0	10	10
	8575/3	Metaplastic carcinoma	0	1	1
	8851/3	Liposarcoma, well differentiated	1	0	1
	8140/3	Adenocarcinoma, NOS	0	1	1

2020 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 66

DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C58	8010/3	Carcinoma, NOS	0	4	4
	8010/6	Carcinoma, metastatic, NOS	0	2	2
	8070/3	Squamous cell carcinoma, NOS	0	2	2
	8140/3	Adenocarcinoma, NOS	0	2	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	0	2	2
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
	8380/6	Endometrioid adenocarcinoma, metastatic, NOS	0	1	1
	8460/3	papillary serous cystadenocarcinoma	0	1	1
	8461/3	Serous surface papillary carcinoma	0	2	2
	8480/3	Mucinous adenocarcinoma	0	1	1
	8720/3	Malignant melanoma, NOS	1	0	1
C53	Cervix		0	41	41
C530	8010/3	Carcinoma, NOS	0	1	1
C531	8070/3	Squamous cell carcinoma, NOS	0	2	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	9	9
	8070/3	Squamous cell carcinoma, NOS	0	17	17
C539	8070/6	Squamous cell carcinoma, metastatic, NOS	0	2	2
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	3	3
	8071/6	Squamous cell carcinoma, keratinizing, metastatic, NOS	0	1	1
	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	0	1	1
	8480/3	Mucinous adenocarcinoma	0	1	1
	8010/3	Carcinoma, NOS	0	3	3
C54	Corpus uteri		0	50	50
C541	8010/6	Carcinoma, metastatic, NOS	0	1	1
	8070/3	Squamous cell carcinoma, NOS	0	1	1
	8070/6	Squamous cell carcinoma, metastatic, NOS	0	3	3
	8071/3	Squamous cell carcinoma, keratinizing, NOS	0	1	1
	8140/3	Adenocarcinoma, NOS	0	3	3
	8010/3	Carcinoma, NOS	0	2	2
C542	8010/6	Carcinoma, metastatic, NOS	0	3	3
	8140/3	Adenocarcinoma, NOS	0	7	7
	8380/3	Endometrioid adenocarcinoma, NOS	0	24	24
	8380/6	Endometrioid adenocarcinoma, metastatic, NOS	0	2	2
	8441/6	Sebaceous adenocarcinoma, metastatic	0	1	1
	8931/3	Endometrial stromal sarcoma, low grade	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1
C55	Uterus		0	2	2
C55	8930/3	Endometrial stromal sarcoma, NOS	0	1	1
	8380/3	Endometrioid adenocarcinoma, NOS	0	1	1

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C56	Ovary		0	2	2
C56	8890/3	Liomyosarcoma, NOS	0	1	1
	8000/3	Neoplasm, malignat	0	1	1
C60, C62 – C63	Male genital organs		89	0	89
C600	8070/3	Squamous cell carcinoma, NOS	1	0	1
C601	8072/3	Squamous cell carcinoma, large cell, nonkeratinizing, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	2	0	2
C609	8072/6	Squamous cell carcinoma, large cell, nonkeratinizing, metastatic, NOS	1	0	1
	8070/3	Squamous cell carcinoma, NOS	1	0	1
C621	8140/3	Adenocarcinoma, NOS	69	0	69
	8140/6	Adenocarcinoma, metastatic, NOS	12	0	12
	8720/3	Malignant melanoma, NOS	1	0	1
C632	8070/3	Squamous cell carcinoma, NOS	1	0	1
C61	Prostate gland		2	0	2
C61	8010/3	Carcinoma, NOS	2	0	2
C62	Testis		82	0	82
C621	8140/3	Adenocarcinoma, NOS	69	0	69
	8140/6	Adenocarcinoma, metastatic, NOS	12	0	12
	8720/3	Malignant melanoma, NOS	1	0	1
C64-C66	Kidney, Renal pelvis & Ureter		26	11	37
C64	8010/3	Carcinoma, NOS	2	1	3
C65	8130/3	Papillary transitional cell carcinoma	0	1	1
	8310/3	Clear cell adenocarcinoma, NOS	3	0	3
	8312/3	Renal cell carcinoma, NOS	18	4	22
	8312/6	Renal cell carcinoma, metastatic, NOS	1	0	1
	8319/3	Collecting duct carcinoma	0	1	1
	8312/6	Renal cell carcinoma, NOS	0	1	1
	8720/3	Malignant melanoma, NOS	1	1	2
	8801/3	Spindle cell sarcoma	1	0	1
C65	8120/3	Transitional cell carcinoma, NOS	0	2	2
C67	Bladder		19	3	22
C670	8130/3	Papillary transitional cell carcinoma	2	0	2
	8130/6	Papillary transitional cell carcinoma, metastatic	0	1	1
	8010/3	Carcinoma, NOS	1	0	1
C671	8130/3	Papillary transitional cell carcinoma	1	0	1
	8130/6	Papillary transitional cell carcinoma, metastatic	1	0	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
C672	8130/3	Papillary transitional cell carcinoma	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C673	8130/3	Papillary transitional cell carcinoma	1	0	1
	8130/3	Papillary transitional cell carcinoma	1	0	1
C674	8010/3	Carcinoma, NOS	2	0	2
C679	8052/3	Papillary squamous cell carcinoma	1	0	1
	8120/3	Transitional cell carcinoma, NOS	1	1	2
	8130/6	Papillary transitional cell carcinoma, metastatic	0	1	1
	8010/3	Carcinoma, NOS	4	0	4
C69-C70	Eye & Meninges		8	1	9
C680	8120/3	Transitional cell carcinoma, NOS	1	0	1
	8120/6	Transitional cell carcinoma, metastatic, NOS	1	0	1
	8130/3	Papillary transitional cell carcinoma	4	0	4
	8140/3	Adenocarcinoma, NOS	1	0	1
	8120/3	Transitional cell carcinoma, NOS	1	0	1
C681	8010/3	Carcinoma, NOS	0	1	1
C71	Brain		14	6	20
C710	9440/6	Glioblastoma, metastatic, NOS	0	1	1
C711	9401/3	Astrocytoma, anaplastic	1	0	1
C712	9440/3	Glioblastoma, NOS	1	0	1
	9401/3	Astrocytoma, anaplastic	0	1	1
C715	9392/3	Ependymoma, anaplastic	1	0	1
C716	8770/3	Mixed pithelioid and spindle cell melanoma	1	0	1
C718	8720/6	Malignant melanoma, metastatic, NOS	1	0	1
C719	9180/3	Osteosarcoma, NOS	0	1	1
	9364/3	Peripheral neuroectodermal tumor	1	0	1
	9380/3	Glioma, malignant	3	2	5
	9380/6	Glioma, malignant, metastatic	1	0	1
	9401/3	Astrocytoma, anaplastic	1	0	1
	9440/3	Glioblastoma, NOS	2	0	2
	9441/3	Giant cell glioblastoma	1	1	2
C73	Thyroid gland		25	88	113
C73	8010/3	Carcinoma, NOS	0	6	6
	8010/6	Carcinoma, metastatic, NOS	1	0	1
	8050/3	Papillary carcinoma, NOS	11	25	36
	8050/6	Papillary carcinoma, metastatic, NOS	0	1	1
	8260/3	Papillary adenocarcinoma, NOS	10	35	45
	8260/6	Papillary adenocarcinoma, metastatic, NOS	0	3	3
	8330/3	Follicular Adenocarcinoma, NOS	1	1	2
	8335/3	Follicular carcinoma, minimally invasive	1	11	12
	8340/3	Papillary carcinoma, follicular variant	1	0	1
	8341/3	Papillary microcarcinoma	0	5	5
	8340/3	Papillary carcinoma, follicular variant	0	1	1

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C74	Adrenal gland		3	1	4
C741	8700/3	Pheochromocytoma, malignant	0	1	1
C749	8370/6	Adrenal cortical carcinoma	1	0	1
	8806/3	Desmoplastic small round cell tumor	1	0	1
	9364/6	Peripheral neuroectodermal tumor, metastatic	1	0	1
C76-C79	Other endocrine glands and relate structures		0	1	1
C780	8010/3	Carcinoma, NOS	0	1	1
C80	Without specification of site		7	4	11
C800	8010/3	Carcinoma, NOS	1	0	1
	8140/3	Adenocarcinoma, NOS	1	0	1
C809	8010/3	Carcinoma, NOS	4	2	6
	8140/3	Adenocarcinoma, NOS	1	1	2
	8140/6	Adenocarcinoma, metastatic, NOS	0	1	1
C81	Hodgkin's lymphoma		9	3	12
C811	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	1	0	1
	9650/3	Hodgkin's lymphoma, NOS	2	0	2
	9695/3	Follicular lymphoma, grade 1	0	1	1
C812	9650/3	Hodgkin's lymphoma, NOS	1	0	1
C817	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9650/3	Hodgkin's lymphoma, NOS	1	0	1
	9650/6	Hodgkin's lymphoma, metastatic, NOS	1	1	2
C819	9650/3	Hodgkin's lymphoma, NOS	3	0	3
C82-C88	Non - Hodgkin's lymphoma		54	45	99
C820	9590/6	Malignant lymphoma, metastatic, NOS	1	0	1
C823	9591/3	Malignant lymphoma, non - Hodgkin, NOS	0	1	1
C824	9590/3	Malignant lymphoma, NOS	1	0	1
	9698/3	Follicular lymphoma, grade 2	1	2	3
C827	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
C829	9590/3	Malignant lymphoma, NOS	0	1	1
	9698/3	Follicular lymphoma, grade 2	0	1	1
C830	9590/6	Malignant lymphoma, metastatic, NOS	1	0	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
	9699/3	Marginal zone B-cell lymphoma, NOS	1	0	1
C833	9590/3	Malignant lymphoma, NOS	0	1	1
	9591/3	Malignant lymphoma, non - Hodgkin, NOS	2	3	5
	9591/6	Malignant lymphoma, non - Hodgkin, metastatic, NOS	0	1	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	11	5	16
	9596/6	Composite Hodgkin and non - Hodgkin lymphoma, metastatic	2	2	4

2020 HOSPITAL-BASED CANCER REGISTRY ANNUAL REPORT



TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 2020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
	9650/3	Hodgkin's lymphoma, NOS	1	1	2
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	6	4	10
	9699/3	Marginal zone B-cell lymphoma, NOS	0	1	1
	9702/6	Mature T-cell lymphoma, metastatic, NOS	1	0	1
	9896/3	Acute myeloid leukemia	1	1	2
C835	9590/6	Malignant lymphoma, metastatic, NOS	1	0	1
C839	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	0	1	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	0	1	1
C840	9699/3	Marginal zone B-cell lymphoma, NOS	0	1	1
C844	9702/3	Mature T-cell lymphoma, NOS	4	1	5
C8449	9702/3	Mature T-cell lymphoma, NOS	0	1	1
C848	9590/3	Malignant lymphoma, NOS	0	1	1
C851	9590/3	Malignant lymphoma, NOS	0	1	1
	9590/6	Malignant lymphoma, metastatic, NOS	0	1	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	1	1	2
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	1	2
C857	9591/3	Malignant lymphoma, non - Hodgkin, NOS	1	0	1
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	1	0	1
C859	9590/3	Malignant lymphoma, NOS	1	0	1
	9590/3	Malignant lymphoma, NOS	0	1	1
	9590/6	Malignant lymphoma, metastatic, NOS	1	0	1
	9591/3	Malignant lymphoma, non - Hodgkin, NOS	1	2	3
	9596/3	Composite Hodgkin and non - Hodgkin lymphoma	4	4	8
	9652/3	Hodgkin lymphoma, mixed cellularity, NOS	1	0	1
	9679/3	Mediastinal large B-cell lymphoma	1	0	1
	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	2	1	3
	9699/3	Marginal zone B-cell lymphoma, NOS	1	0	1
	9896/3	Acute myeloid leukemia	1	0	1
C884	9590/6	Malignant lymphoma, metastatic, NOS	0	1	1
	9699/3	Marginal zone B-cell lymphoma, NOS	2	0	2
C90	Multiple myeloma		15	21	36
C900	9732/3	Multiple myeloma	14	19	33
	9732/6	Multiple myeloma, metastatic	0	1	1
C902	9732/3	Multiple myeloma	1	1	2
C91-C95	Leukaemia		34	26	60
C910	9801/3	Acute Leukaemia, NOS	2	0	2
	9835/3	Precursor cell lymphoblastic leukemia, NOS	4	3	7
C911	9800/3	Leukaemia, NOS	1	0	1
	9801/3	Acute Leukaemia, NOS	0	1	1
	9823/3	B-cell chronic lymphocytic leukemia/small lymphoma	1	0	1
	9863/3	Chronic myeloid Leukaemia, NOS	0	2	2
	9961/3	Chronic myeloproliferative disease, NOS	1	0	1

TABLE 66 DISTRIBUTION OF NEW CANCER PATIENTS BY MORPHOLOGY AND SITE : 202020

ICD-10	Code	Morphology Description	Number of cases		
			Male	Female	Total
C920	9801/3	Acute Leukaemia, NOS	2	0	2
	9861/3	Acute myeloid Leukaemia, NOS	8	15	23
	9861/6	Acute myeloid Leukaemia, metastatic, NOS	2	0	2
C921	9801/3	Acute Leukaemia, NOS	3	2	5
	9861/3	Acute myeloid Leukaemia, NOS	2	1	3
	9863/3	Chronic myeloid Leukaemia, NOS	1	1	2
	9863/6	Chronic myeloid Leukaemia, metastatic, NOS	1	0	1
C924	9861/3	Acute myeloid Leukaemia, NOS	1	0	1
C925	9801/3	Acute Leukaemia, NOS	1	0	1
	9861/3	Acute myeloid Leukaemia, NOS	1	0	1
C950	9680/3	Malignant lymphoma, large B-cell, diffuse, NOS	1	0	1
	9861/3	Acute myeloid Leukaemia, NOS	0	1	1
C959	9861/3	Acute myeloid Leukaemia, NOS	1	0	1
C965	8012/3	Large cell carcinoma, NOS	1	0	1


TABLE 67
DISTRIBUTION OF NEW CANCER PATIENTS BY FOLLOW UP AND GENDER: 2016-2020

Follow up status	Male		Female		Total	
	Number	Percent	Number	Percent	Number	Percent
Alive	2237	52.5	2791	68.3	5028	60.2
Deaths	2023	47.5	1295	31.7	3318	39.8
Total	4260	100.0	4086	100.0	8346	100.0

Survey: 3 August 2021

TABLE 68
THE LEADING PRIMARY SITES OF NEW CANCER BY GENDER: 2016-2020

Ordinal	Primary site	Male		Female		Total	
		Number	Percent	Number	Percent	Number	Percent
1	Trachea, bronchus & lung	610	14.3	369	9.0	979	11.7
2	Colon & Rectosigmoid junction & Rectum	595	14.0	375	9.2	970	11.6
3	Breast	17	0.4	931	22.8	948	11.4
4	Liver & intrahepatic bile ducts	551	12.9	153	3.7	704	8.4
5	Thyroid gland	104	2.4	393	9.6	497	6.0
6	Non-Hodgkin's lymphoma	252	5.9	185	4.5	437	5.2
7	Prostate gland	416	9.7	0	0.0	416	5.0
8	Cervix	0	0.0	299	7.3	299	3.6
9	leukaemia	143	3.4	126	3.1	269	3.2
10	Skin	107	2.5	130	3.2	237	2.8

Survey: 3 August 2021

TABLE 69 THE LEADING PRIMARY SITES OF NEW CANCER BY FOLLOW UP AND GENDER: 2016-2020						
Ordinal	Primary site	Alive		Deaths		Total
		Male	Female	Male	Female	
1	Trachea, bronchus & lung	172	169	438	200	979
2	Colon & Rectosigmoid junction & Rectum	382	244	213	131	970
3	Breast	15	774	2	157	948
4	Liver & intrahepatic bile ducts	177	43	374	110	704
5	Thyroid gland	96	377	8	16	497
6	Non-Hodgkin's lymphoma	151	120	101	65	437
7	Prostate gland	332	0	84	0	416
8	Cervix	0	206	0	93	299
9	leukaemia	67	63	76	63	269
10	Skin	81	110	26	20	237

Survey: 3 August 2021

TABLE 70 THE 60 MONTHS SURVIVAL TIME (MEDIAN) TOP 6 BY GENDER IN 2016 - 2020			
Ordinal	Primary site	Male	Female
1	Trachea, bronchus & lung	6.55	8.83
2	Colon & Rectosigmoid junction & Rectum	12.02	11.40
3	Breast	12.50	10.53
4	Liver & intrahepatic bile ducts	5.65	5.09
5	Thyroid gland	13.46	15.44
6	Non-Hodgkin's lymphoma	8.51	9.25

Survey: 3 August 2021



FIGURE 32: THE 60 MONTHS SURVIVAL RATE (TOP 6) IN 2016 – 2020





FIGURE 33: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY MALE IN 2016 – 2020







FIGURE 34: THE 60 MONTHS SURVIVAL RATE (TOP 6) BY FEMALE IN 2016 – 2020



Phramongkutklo Hospital 315 Ratchawithi Road, Bangkok 10400, Thailand.





PHRAMONKUTKLAO HOSPITAL

EXCELLENT CENTER OF CANCER CARE 2020

Oncology Unit and Epidemiology Unit,
Phramongkutklao Hospital.

315 Ratchawithi Road, Bangkok 10400, Thailand.

Tel. : + 66 2763 3925, + 66 2763 3047

Fax. : + 66 2354 7780

Email : ceupmk@hotmail.com

Website : <http://ceu.pmk.ac.th>